Möchten Sie immer auf dem neuesten Stand bleiben?

PITTSBURGH, July 08, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has entered into a standby equity purchase...

PITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today the company has successfully developed 3D organoid models...

PITTSBURGH, May 27, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, today issued the following statement regarding its dispute with Renovaro,...

PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor samples and drug response...

Latest developments expand Predictive’s AI-driven drug discovery platform to include biomarker discovery and drug repurposing With the global biomarker discovery market valued at $14.5 billion in...

Predictive Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

New indications discovered by applying active machine learning and using samples from the company’s vast biobank of live-cell tumors specimens Builds upon Predictive’s biomarker discovery platform...

PITTSBURGH, April 01, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities,...

Company successfully developed predictive models derived from 21 unique compounds from the Natural Products Discovery Core at the University of Michigan Tumor response models for novel compounds...

Deal positions STREAMWAY® Systems with an established market leader to drive accelerating growth Transaction allows Predictive Oncology to be highly focused on its core AI-driven drug discovery...